Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 8/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 7/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 7/20 | 0.44 |
| ▸ | GABRP | O00591 | 6/20 | 0.44 |
| ▸ | GABRD | O14764 | 6/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.44 |
| ▸ | GABRE | P78334 | 6/20 | 0.44 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 0.44 |
| ▸ | GABRG3 | Q99928 | 6/20 | 0.44 |
| ▸ | GABRQ | Q9UN88 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10228362 | 0.86 | CYP1A2 (0.50) | CYP1A2NOTUMGABRA2GABRA1GABRG2 | |
| SCHEMBL23212158 | 0.84 | KMO (0.33) | NOTUMGABRA2GABRA1GABRG2GABRB3 | |
| SCHEMBL294157 | 0.81 | CYP1A2 (0.49) | CYP1A2GABRA2GABRA1GABRG2GABRB3 | |
| SCHEMBL2130286 | 0.80 | ALDH1A1 (0.44) | CYP1A2NOTUMGABRA2GABRA1GABRG2 | |
| SCHEMBL13472450 | 0.79 | ALDH1A1 (0.47) | CYP1A2GABRA2GABRA1GABRG2GABRB3 | |
| SCHEMBL1660845 | 0.79 | DGAT1 (0.36) | NOTUMMAPTNPC1LMNAALDH1A1 | |
| SCHEMBL20074703 | 0.77 | SLC34A1 (0.53) | NOTUMMAPTLMNAKMT2A | |
| SCHEMBL11528320 | 0.77 | CYP1A2 (0.45) | CYP1A2GABRA2GABRA1GABRG2GABRB3 | |
| SCHEMBL23361722 | 0.76 | POLB (0.52) | LMNAALDH1A1SMN1; SMN2RAB9ANPSR1 | |
| SCHEMBL2823270 | 0.76 | CYP1A2 (0.51) | CYP1A2NOTUMGABRA2GABRB2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4308125-B1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12606570-B2 | Deuterated compounds and imaging agents for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20240190892-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-06-13 | — | — | US | disclosed |
| CN-117545512-A | Deuterated compounds and imaging agents for imaging huntingtin | CHDI基金会股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| EP-4308125-A1 | PLASMA KALLIKREIN INHIBITORS | Merck Sharp & Dohme LLC (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20230295119-A1 | SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GOSSAMER BIO SERVICES INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295119-A1 | SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GOSSAMER BIO SERVICES INC (US) | 2023-09-21 | — | — | US | disclosed |
| EP-4136073-A1 | SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | Gossamer Bio Services, Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| CN-115702145-A | Substituted pyridines for the treatment of inflammatory diseases | 戈萨默生物服务公司 | 2023-02-14 | — | — | CN | disclosed |
| US-20220372045-A1 | DEUTERATED COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2022-11-24 | — | — | US | disclosed |
| WO-2010020432-A8 | COMPOUNDS FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED (BS) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010020432-A2 | COMPOUNDS FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2010-02-25 | — | — | WO | disclosed |
| US-20090036419-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-20090036419-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-20090036419-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| WO-2009006389-A2 | PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009006389-A2 | PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| US-4129737-A | Process for the preparation of an 8-alkyl-5-oxo-5,8-dihydro-pyrido(2,3-d)pyrimidine-6-carboxylic acid | LABORATOIRE ROGER BELLON (FR) | 1978-12-12 | — | — | US | disclosed |
| US-4034094-A | 8-Alkyl-5-oxo-5,8-dihydro-pyrido(2,3-d)pyrimidine-6-carboxylic acids for treating urinary tract infections | LABORATOIRE ROGER BELLOW (FR) | 1977-07-05 | — | — | US | disclosed |
| US-3950338-A | BACTERICIDES | LABORATOIRE ROGER BELLON (FR) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606570-B2 | Deuterated compounds and imaging agents for imaging huntingtin protein | HTT, HYPK, ATXN2 | CYP1A2 4686/4885NOTUM 3177/4885GABRA2 3196/4885 |
| US-20230295119-A1 | SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | IRAK3, TYK2, IRAK2 | CYP1A2 490/4885NOTUM 4775/4885GABRA2 2641/4885 |
| US-20090036419-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | CYP1A2 4510/4885NOTUM 2842/4885GABRA2 4313/4885 |
| US-20240190892-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, SERPINE1, SERPINB1 | CYP1A2 2976/4885NOTUM 1977/4885GABRA2 4766/4885 |
| US-20220372045-A1 | DEUTERATED COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, HIRIP3 | CYP1A2 4879/4885NOTUM 3992/4885GABRA2 3112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.